CARDIAC RESYNCHRONIZATION AND DEFIBRILLATOR THERAPY (CRT-D) OR CRT ALONE (CRT-P) IN PATIENTS WITH DILATED CARDIOMYOPATHY AND HEART FAILURE WITHOUT LATE GADOLINIUM ENHANCEMENT (LGE) CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) HIGH-RISK MARKERS - CRT-REALITY STUDY - STUDY DESIGN AND RATIONALE

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27283933%3A_____%2F21%3A00009786" target="_blank" >RIV/27283933:_____/21:00009786 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/22:10435465 RIV/00159816:_____/22:00077899 RIV/00023001:_____/22:00083421 RIV/00098892:_____/22:10157606 a 5 dalších

Výsledek na webu

<a href="https://biomed.papers.upol.cz/pdfs/bio/2022/02/08.pdf" target="_blank" >https://biomed.papers.upol.cz/pdfs/bio/2022/02/08.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2021.015" target="_blank" >10.5507/bp.2021.015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CARDIAC RESYNCHRONIZATION AND DEFIBRILLATOR THERAPY (CRT-D) OR CRT ALONE (CRT-P) IN PATIENTS WITH DILATED CARDIOMYOPATHY AND HEART FAILURE WITHOUT LATE GADOLINIUM ENHANCEMENT (LGE) CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) HIGH-RISK MARKERS - CRT-REALITY STUDY - STUDY DESIGN AND RATIONALE

Popis výsledku v původním jazyce

Background: Primary preventive implantation of implantable defibrillator (ICD) is according to current guidelines indicated in patients with heart failure NYHA (New York Heart Association) class II/III and LVEF b35%. Thanks to advances in heart failure pharmacotherapy, a decrease in mortality could render a benefit of ICD insufficient to justify its implantation in some patients. Methods: Study design: multicenter, prospective, randomized, controlled trial evaluating the benefit of implantation of Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in non-ischemic patients with reduced left ventricle ejection fraction (LVEF) and optimal pharmacotherapy without significant mid-wall myocardial fibrosis detected by cardiac magnetic resonance (CMR). The primary end-point: Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The secondary end-points: Sudden cardiac death, cardiovascular death, resuscitated cardiac arrest or sustained ventricular tachycardia, device-related complications, and change in quality of life. Course of the study: After a pharmacotherapy is optimized and significant mid-wall myocardial fibrosis excluded, patients will be randomized 1:1 to CRT-P or CRT-D implantation. Discussion: If our hypothesis is confirmed, this could provide evidence for the management of these patients with a significant impact on common daily praxis and health care expenditures.

Název v anglickém jazyce

CARDIAC RESYNCHRONIZATION AND DEFIBRILLATOR THERAPY (CRT-D) OR CRT ALONE (CRT-P) IN PATIENTS WITH DILATED CARDIOMYOPATHY AND HEART FAILURE WITHOUT LATE GADOLINIUM ENHANCEMENT (LGE) CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) HIGH-RISK MARKERS - CRT-REALITY STUDY - STUDY DESIGN AND RATIONALE

Popis výsledku anglicky

Background: Primary preventive implantation of implantable defibrillator (ICD) is according to current guidelines indicated in patients with heart failure NYHA (New York Heart Association) class II/III and LVEF b35%. Thanks to advances in heart failure pharmacotherapy, a decrease in mortality could render a benefit of ICD insufficient to justify its implantation in some patients. Methods: Study design: multicenter, prospective, randomized, controlled trial evaluating the benefit of implantation of Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in non-ischemic patients with reduced left ventricle ejection fraction (LVEF) and optimal pharmacotherapy without significant mid-wall myocardial fibrosis detected by cardiac magnetic resonance (CMR). The primary end-point: Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The secondary end-points: Sudden cardiac death, cardiovascular death, resuscitated cardiac arrest or sustained ventricular tachycardia, device-related complications, and change in quality of life. Course of the study: After a pharmacotherapy is optimized and significant mid-wall myocardial fibrosis excluded, patients will be randomized 1:1 to CRT-P or CRT-D implantation. Discussion: If our hypothesis is confirmed, this could provide evidence for the management of these patients with a significant impact on common daily praxis and health care expenditures.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

173-179

Kód UT WoS článku

000731340300001

EID výsledku v databázi Scopus

—